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Abstract: The HLA region encodes several molecules that play key roles in the immune system. Strong association be-
tween the HLA region and autoimmune disease (AID) has been established for over fifty years. Association of compo-
nents of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including 
rheumatoid arthritis, type 1 diabetes and Graves’ disease. Molecules encoded by this region play a key role in exogenous 
antigen presentation to CD4+ Th cells, indicating the importance of this pathway in AID initiation and progression. Al-
though other components of the HLA class I and III regions have also been investigated for association with AID, apart 
from the association of HLA-B*27 with ankylosing spondylitis, it has been difficult to determine additional susceptibility 
loci independent of the strong linkage disequilibrium (LD) with the HLA class II genes. Recent advances in the statistical 
analysis of LD and the recruitment of large AID datasets have allowed investigation of the HLA class I and III regions to 
be re-visited. Association of the HLA class I region, independent of known HLA class II effects, has now been detected 
for several AIDs, including strong association of HLA-B with type 1 diabetes and HLA-C with multiple sclerosis and 
Graves’ disease. These results provide further evidence of a possible role for bacterial or viral infection and CD8+ T cells 
in AID onset. The advances being made in determining the primary associations within the HLA region and AIDs will not 
only increase our understanding of the mechanisms behind disease pathogenesis but may also aid in the development of 
novel therapeutic targets in the future. 
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INTRODUCTION  
  Autoimmune diseases (AIDs) including type 1 diabetes 
(T1D), multiple sclerosis (MS), rheumatoid arthritis (RA), 
Graves’ disease (GD), ankylosing spondylitis (AS) and sys-
temic lupus erythematosus (SLE) affect over 4% of the 
western population and involve the generation of autoanti-
bodies against self antigen/s. In many cases lymphocytic 
infiltration of a target organ/s and autoimmune destruction is 
also observed. These diseases are often chronic and debilitat-
ing and, although treatments are available, many are inade-
quate [1] providing the impetus for a greater understanding 
of the disease mechanisms and the development of novel 
therapeutic agents. Antigen presentation and T cell activation 
appear to be key to triggering an autoimmune response [2] 
prompting investigation of many genes within this pathway 
for association with AID including several within the major 
histocompatibility complex (MHC).  
  The MHC, also known in humans as the human leuko-
cyte antigen (HLA) region, encompasses 7.6Mb on chromo-
some 6p21 and is the most gene dense region within the hu-
man genome encoding 252 expressed loci [3] including sev-
eral key immune response genes. The region can be subdi-
vided into the extended class I, classical class I, classical 
class III, classical class II and extended class II regions   
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(Fig.  1) and contains the largest degree of polymorphism 
within the genome [4]. It also exhibits the most dense link-
age disequilibrium (LD) [5], extending up to 540kb, which 
compares with distances of between 1-173kb seen in the rest 
of the genome [6, 7]. The extent of LD within the region has 
proved challenging when trying to tease out the exact loca-
tion of etiological variants. Most studies have focussed on 
the role of HLA class II encoded HLA-DR and –DQ mole-
cules, which present exogenous antigens for recognition by 
CD4+ T helper (Th) cells. Strong associations with almost 
all AIDs have been detected (see Table 1).  
ASSOCIATION OF THE HLA CLASS II REGION 
WITH AID 
  Early experiments investigating association of HLA-DR 
and -DQ with AID in T1D indicated a strong association of 
the DRB1*03 and DRB1*04 alleles [8-10]. A stronger asso-
ciation with the DQB1 locus alone was reported when an 
allele encoding aspartic acid (Asp) at position 57 of DQB1 
was found to be associated with resistance to T1D, while an 
allele encoding a neutral residue, such as alanine (Ala) or 
serine (Ser) at position 57 conferred susceptibility [11-13]. 
This molecule forms a critical residue in peptide binding 
pocket nine (P9) of the DQB1 binding pocket involved in 
antigen presentation and T cell receptor (TCR) interaction. 
It’s carboxylate group forms a salt bridge with arginine 
(Arg) at position 57 of the DQA1 chain that stabilizes the 
heterodimer between the DQA1 and DQB1 chains [13]. The 
presence of Asp at this position could alter the stability of 454    Current Genomics, 2007, Vol. 8, No. 7  Gough and Simmonds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). a) Diagrammatic representation of the HLA region on chromosome 6p21, b) More detailed diagrams of common AID genes within 
the HLA class I and class II region c) Representation of endogenous antigen presentation by HLA class I classical molecules (including HLA-
A, -B and –C). Endogenous antigen generated in the cytosol is degraded within the proteasomes and then transported into the rough endo-
plasmic reticulum (RER) through the TAP1/TAP2 complex. Antigen is then bound by HLA class I molecules in connection with 2M and 
then once bound the molecule is exported to the cell surface for recognition by CD8+ T cells and natural killer (NK) cells. Exogenous antigen 
presentation by HLA class II classical molecules (including HLA-DR and –DQ) is also represented. Exogenous antigen is imported into the 
cell and then enters the endosytic pathway (encompassing the early endosome, late endosome and lysosome) where the antigen is degraded. 
At the same time HLA class II molecules complexed with the invariant chain move from the RER where they are synthesised to the endocytic 
pathway. As the HLA class II/Invariant chain complex moves into the increasing more acidic compartment of the endocytic pathway the in-
variant chain is digested, leaving only CLIP bound. The CLIP is then replaced with degraded antigen and then the HLA class II mole-
cule/antigen complex is exported to the surface of the cell for presentation to CD4+ T helper (Th) cells. PSMB = Proteasome subunit B –type, 
TAP = Transporters associated with antigen presentation, 2M = 2 Microglobulin, CLIP = class II associated invariant chain. The HLA Region and Autoimmune Disease  Current Genomics, 2007, Vol. 8, No. 7    455 
Table 1.  Summary of the Major Associations Within the HLA Class II and Class I Region with Common Autoimmune Diseases 
HLA Class II Effects  HLA Class I Effects 
Predisposing Protective 
AUTOIMMUNE DISEASE 
Predisposing Protective 
   
Ankylosing spondylitis 
B*2701 
B*2704 
B*2705 
B*2706 
B*2709 
DR3  
DRB1*08 
DR7 
Graves’ disease 
C*07 
B*08 
C*16 
C*03 
B*44 
DR4 
DR3 
DR7 
Hashimoto’s thyroiditis 
   
DR3    Myasthenia Gravis     
DR3    Addison’s disease     
Shared epitope = 
DRB1*0101 
DRB1*0102 
DRB1*0401 
DRB1*0404 
DRB1*0405 
DRB1*0408 
DRB1*1001 
DRB1*1402 
DRB1*0103 
DRB1*07 
DRB1*1201 
DRB1*1301 
DRB1*1501  Rheumatoid arthritis 
   
DQ2 
DQ8 
 
Celiac disease 
   
DR15 DR14 
Multiple sclerosis 
C*05 
C*15 
C*01 
DR3 
DR4 
DQB1 position 57 
DR15 
DR14  Type 1 diabetes 
B*39 
B*18 
A*24 
A*01 
A*11 
A*31 
DR3 
DR8 
DR15 
 
Systemic lupus erythematosus 
   
Both allelic and haplotype associations have been shown.  = Further studies needed to determine association. DR3 = DRB1*03-DQB1*02-DQA1*0501, DR4 = DRB1*04-
DQB1*0302-DQA1*0301, DR7 = DRB1*07-DQB1*02-DQA1*02, DR14 = DRB1*14-DQB1*06-DQA1*0102, DR15 = DRB1*15-DQB1*06-DQA1*01, DQ8 = DQB1*0302 and 
DQ2 = DQB1*0201. 
the molecule and/or antigen presenting repertoire, thus mak-
ing the molecule more prone to binding autoreactive anti-
gens. Although this may provide an interesting mechanism 
for association of the HLA class II region with T1D, further 
studies have demonstrated a potential role for other residues 
in DQB1 binding pocket P9 and DRB1 binding pockets P1 
and P4 in disease susceptibility [13].  
  Association with RA is only seen at DRB1, with other 
associations with DQB1 [14] almost certainly the result of 
LD with DRB1 [15, 16]. Originally association was attrib-
uted to DRB1*04 [17] but other associations have subse-
quently been reported. Work by Gregerson, et al, showed 
that association of DRB1 alleles (DRB1*0101, DRB1*0102, 
DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, 
DRB1*1001 and DRB1*1402) [18, 19] was due to similari-
ties within the DRB1 peptide domain at positions 70 
through to 74, with these alleles containing similar se-
quences (QKRAA/QRRAA/RRRAA) termed the ‘shared 
epitope’ [18]. Amino acid changes within the shared epitope 
have been postulated to differentiate the predisposing alleles 
from the protective DRB1*0103, DRB1*07, DRB1*1201, 
DRB1*1301 and DRB1*1501 alleles [2, 15, 20]. Recent 
work on the shared epitope has suggested a new model, 
whereby the shared epitope only consists of positions 72-
74, and rather than being essential for disease susceptibility, 
positions 70 and 71 have been proposed to modulate asso-
ciation [21, 22]. Further verification of this hypothesis, re-
defining the shared epitope, is required.  
  Association of DRB1 position 74 of the share epitope is 
not unique to RA. In GD, comparison of the predisposing 
DRB1*03 and protective DRB1*07 molecules showed 
DRB1*03 containing a positively charged Arg at 74 and 
DRB1*07 containing a non-charged polar glutamine (Gln) at 
this position. Position 74 has also been shown to differenti-456    Current Genomics, 2007, Vol. 8, No. 7  Gough and Simmonds 
ate between the lower risk DRB1*0403 and *0406 T1D al-
leles, which contain a negatively charged glutamic acid 
(Glu), compared to the high risk DRB1*0401 allele which 
contain a non-charged polar Ala [23-26]. Interestingly the 
DRB1*07 haplotype is also protective against T1D and RA 
[27-29]. Amino acid 74 spans several binding environments 
involved in autoantigen binding/presentation and T cell anti-
gen receptor docking and interaction [30], suggesting that 
changes within peptide and TCR binding could determine 
which amino acids are presented to the immune system.  
  Further work on DRB1 and DQB1 showed that there was 
LD between these molecules and, along with DQA1, they 
were found to form part of extended haplotypes DRB1*03-
DQB1*02-DQA1*0501 (DR3) and DRB1*04-DQB1*0302-
DQA1*0301 (DR4) associated with T1D [2, 31]. Overlap 
between HLA class II associations has been seen between 
AIDs, with DR3 also being associated with GD, SLE and 
HT, therefore, being termed the ‘autoimmunity haplotype’ 
(See Table 1 for list of common AID HLA class II associa-
tions). DR4 is also associated with other AIDs, including 
HT. Statistical modelling techniques, including logistic re-
gression analysis, have been employed to determine which 
components of the DRB1-DQB1-DQA1 haplotype contain 
the etiological variants associated with AID. In GD this ap-
proach was successful in determining that DQB1 was unable 
to explain association with disease, narrowing down the lo-
cation of the etiological variant within the class II region to 
either DRB1 or DQA1 [32].  
  Sharing of susceptibility loci between AIDs is not unique 
to the HLA region with variants within CTLA-4, PTPN22 
and CD25 also being shared [2, 33-35]. There are however 
distinct differences between the AIDs, with the DR15 
(DRB1*15- DQB1*0602-DQA1*0102) haplotype strongly 
predisposing for MS [12, 36], whilst protecting against T1D. 
The observation, therefore, of a number of different DR 
and/or  DQ associations, with AID suggests that there are 
common and unique disease pathways for each AID which 
may, in part, be explained by the presentation of different 
disease-specific autoantigens [1].  
HLA CLASS II DISEASE MECHANISMS 
  The role played by the HLA-DR/-DQ molecules in ex-
ogenous antigen presentation to CD4+ Th cells helps to ex-
plain their association with several AIDs (see Fig. 1). Ex-
ogenous peripheral antigens are internalized via antigen pre-
senting cells (APC) and are degraded into 13-18 amino acid 
residue peptides, preferentially bound by HLA class II mole-
cules, in the increasingly acidic compartments of the endo-
cytic pathway. HLA class II molecules are synthesized in the 
rough endoplasmic reticulum (RER) where they associate 
with the invariant chain (Ii) to prevent endogenous peptide 
binding. The HLA class II molecule is then routed to the 
endocytic pathway, where Ii is degraded, leaving a short 
fragment of the Ii class II-associated invariant chain peptide 
(CLIP) bound, which is then exchanged for peptide [37]. The 
HLA class II peptide complex is then transported to the cell 
surface for recognition by CD4+ Th cells, which determine 
whether an immune response is mounted. If an immune re-
sponse is mounted CD4+ Th cells activate naive B cells to 
produce antibodies, or in the case of self-antigens autoanti-
bodies, and aid in macrophage recruitment. Activated 
autoreactive CD4+ Th cells against a variety of exogenous 
autoantigens, including pancreatic beta cells, thyroid compo-
nents and myelin, have been detected in TID, GD and MS 
respectively [38], suggesting a role in disease susceptibility. 
  Several non-mutually exclusive mechanisms have been 
proposed to explain association of DR/DQ with AIDs: 
i)  Variation in binding groves of associated DR/DQ mole-
cules could lead to preferential presentation of only a 
specific limited set of self peptides or low affinity self 
peptides may allow autoreactive T cells to escape 
tolerance and enter the periphery. This could affect 
thymic T cell education, causing incomplete thymic 
tolerance and a Th and T regulatory (Treg) cell 
population that does not recognize all self molecules.  
ii)  Polymorphic residues of the TCR-exposed surfaces of 
DR/DQ could select autoreactive T cells or fail to select 
a good Treg population. It has been proposed that the 
protective effects seen with specific HLA molecules 
could be due to the generation of Treg cells that are 
able to keep autoreactive T cells in check and prevent 
autoimmunity [39]. Studies in RA have shown Treg 
populations to be compromised [40], suggesting that 
RA could be associated with a failure to protect rather 
than a predisposition to disease.  
iii)  Promiscuous restriction where some TCRs will use a 
series of different restriction elements to bind to and, 
therefore, interact with a wider variety of different pep-
tides.  
iv)  Preferential binding in DR/DQ heterozygous subjects 
could be occurring through epitope stealing by one 
HLA molecule over another which, depending on TCR 
restriction of CD4+ Th cells, could affect whether an 
immune response is mounted [41].  
v)  Presentation of endogenous antigens by HLA class II. 
Although class II molecules traditionally present ex-
ogenous antigens and class I present endogenous anti-
gens (see Fig. 1), this system is not absolute and pres-
entation of endogenous antigens by class II and exoge-
nous antigens by class I can be seen [42, 43]. This 
could alter how these antigens are presented to the im-
mune system and the response triggered.  
  These hypotheses suggest a series of potential mechanis-
tic pathways by which the HLA class II molecules could be 
involved in disease onset by altering the Th and Treg cell 
repertoire or through changes in how the antigen is recog-
nized in the periphery. 
EVIDENCE FOR ROLE OF HLA CLASS I IN DISEASE 
  Association of HLA class I molecules, in particular 
HLA-A, -B and –C, has been detected for several AIDs. 
HLA-B*27 has been known for many years to predispose to 
AS, and is present in over 90% of European AS patients 
[44]. Of the 31 HLA-B*27 suballeles detected to date [45] 
the B*2701, B*2704 and B*2705 alleles are strongly predis-
posing for AS [45, 46], whereas the B*2706 and B*2709 
alleles are protective [46, 47]. Interestingly, the B*2705 only 
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Asp or histidine (His), respectively, which is known to alter 
peptide specificity and T cell recognition [45, 48]. Although 
HLA-A, -B and –C are located in the HLA class I region, 
they exhibit LD with the HLA class II encoded DR/DQ 
haplotypes. The presence of this strong LD with the HLA 
class II region has made it difficult to identify independent 
effects for the class I region with any AIDs except AS which 
exhibits no strong class II associations, although further con-
firmation of potential HLA class II effects in AS is needed 
[49]. The utilization of larger datasets and the development 
of more advanced statistical analysis, has enabled re-
investigation of the HLA class I region as an independent 
general AID locus. 
  Work in T1D identified a microsatellite D6S2223 4.9kb 
telomeric of DQ in the extended class I region, as being as-
sociated with a reduction in the risk conferred by the DR3 
extended haplotype on disease [50], with further work nar-
rowing the association to a region encompassing the class III 
and HLA-B/-C gene regions [51]. Work in the NOD mouse 
also suggested the presence of independent risk factors 
within the MHC, independent of the MHC class II [52], with 
further genetic studies in humans confirming the presence of 
HLA class II independent T1D susceptibility loci within the 
class I region [53, 54]. More recently, screening of a total of 
1729 polymorphisms across the whole HLA region in sev-
eral independent Caucasian T1D datasets, revealed evidence 
of a secondary peak of association for T1D independent of 
known DQB1 and DRB1 effects, due to the HLA-B locus 
(Pcombined = 2.01 x 10
-19) with the B*39 allele consistently 
associated with T1D and some evidence for an effect of 
B*18 [55]. Association of HLA-A was also detected (Pcombined 
= 2.35 x 10
-13) [55], with predisposing effects for A*24 and 
protective effects for A*01, A*11 and A*31 identified.  
  The presence of additional susceptibility loci within the 
HLA class I gene region has also been detected for MS. 
HLA class II independent association of two microsatellite 
markers (D6S1683 and D6S265) in close proximity to the 
HLA class I region was reported [56]. Association studies 
within a small Swedish dataset demonstrated a predisposing 
effect for the A*0301 allele and a protective effect for the 
A*0201 allele in patients with MS [57], independent of the 
known DR15 association, with further studies confirming the 
protective effect of A*0201 [58]. A recent large MS case 
control study further confirmed an independent protective 
effect of A*0201 (P = 7 x 10
-12), although failed to detect an 
independent association for A*0301 [59]. Using a combina-
tion of microsatellite markers, tagging single nucleotide po-
lymorphisms (SNPs) and classical HLA typing, the Interna-
tional MS genetics consortium detected an independent pro-
tective effect for C*05 (P = 3.3 x 10
-5), in both a family and 
case control dataset [60]. Although this study did not find 
any support for independent HLA-A effects, they could not 
rule out an effect at this locus [60]. Interestingly when HLA-
B and –C were screened for association with GD and logistic 
regression analysis applied to see if these effects were inde-
pendent of known HLA-DR/-DQ affects, HLA-C, and to a 
lesser extent HLA-B, produced stronger association (P = 1.20 
x 10
-20 and P = 1.54 x 10
-6, respectively) with disease than 
the previously established HLA class II effect, suggesting a 
key role in disease susceptibility [32].  
HLA CLASS I DISEASE MECHANISMS 
  HLA class I molecules present endogenous antigens, 
such as those derived from viruses and intracellular bacteria, 
for recognition by the immune system (see Fig. 1). This 
process involves ubiquitination of endogenous cytosolic pro-
teins and then degradation into short 8-16 amino acid pep-
tides, optimal for HLA class I binding. These are subse-
quently transported into the RER where they bind HLA class 
I molecules combined with 2 microglobulin (2M), before 
exiting the RER and being transported to the cell surface 
[37]. HLA class I presented antigen is then recognized by 
CD8+ T cells and natural killer (NK) cells. Once CD8+ T 
cells become activated, functional effector T lymphocytes 
(CTLs) are produced which possess lytic capabilities and 
also play a role in generating CD8+ T memory cells, acting 
as part of both the innate and adaptive immune responses. 
Activated NKs act before clonal expansion and differentia-
tion of CD8+ T cells and compliment the CTL response. 
They act as one of the first lines of innate immune defence 
by producing lymphokines, including interferons, which aid 
in the recruitment of additional cells to the site of inflamma-
tion [61] and also produce cytokines and chemokines that 
have a cytolytic activity aiding cell destruction.  
  There is increasing evidence for a role of CD8+ T cells in 
AID. Knocking out MHC class I expression in the SLE 
prone mouse suggested an important role for CD8+ T cells in 
autoimmunity as it failed to develop SLE [62]. Further mod-
els suggested a key role for CD8+ T cells in AID progres-
sion, rather than in initiation [63, 64]. Recently CD8+ T cells 
have been detected in the peripheral blood, cerebrospinal 
fluid and lesions of MS sufferers and were shown to destroy 
multiple central nervous system cell substrates, including 
myelin peptides [65, 66]. Suppressor CD8+ T cells have also 
been found to be decreased in relapsing MS subjects [66]. 
Work in T1D has demonstrated CD8+ specific T cell re-
sponses and a potential role for defective CD8+ T suppressor 
cells [67-69] with CD8+ T cells responses also shown to be 
important in SLE and GD [70].  
  Several hypotheses have been suggested to explain how 
variation in HLA class I genes could trigger autoimmunity. 
HLA class I molecules play a role in presenting endogenous 
antigens, including those derived from viruses and/or bacte-
ria, which have been proposed to be key environmental trig-
gers for AID (see Table 2 for a list of proposed viral triggers 
of AID). Viral/bacterial antigens may trigger AID through 
molecular mimicry and via acting as superantigens. Molecu-
lar mimicry occurs when microbial antigens that are suffi-
ciently similar to self-antigens activate autoreactive T-cells 
that can cross react with self antigen triggering autoimmu-
nity. Viral/bacterial antigens could also act as superantigens, 
producing a strong non-specific immune response that then 
cross reacts attacking other tissues in the body [71, 72]. Vi-
ruses can also alter HLA class I and II expression, poten-
tially leading to greater antigen presentation to CD8+ T cells, 
with certain alleles more prone to viral/bacteria manipulation 
[73]. During viral infection soluble HLA levels, involved in 
regulating the immune response, have also been shown to be 
increased in RA patients, the level of which is dependent on 
HLA allele present [74, 75]. If confirmed these mechanisms 458    Current Genomics, 2007, Vol. 8, No. 7  Gough and Simmonds 
could also help validate the role of viral/bacterial infection in 
AID onset.  
  HLA class I molecules could also be associated with AID 
due to their role in inhibiting NK cell activity. NK cell cyto-
toxic activity is controlled by a balance between activating 
and inhibitory receptors on their surface [76]. Activation 
signals are blocked by inhibitory signals produced through 
interaction of killer immunoglobulin-like receptors (KIR) 
with a variety of HLA class I molecules loaded with peptide 
[76, 77]. If HLA class I expression is normal then NK cell 
mediated destruction is inhibited. For example, there are two 
sets of KIRs, 2DL1 and 2DL2/2DL3 which recognize spe-
cific sets of HLA-C molecules, group C1 molecules (con-
taining C*02, *04, *05 and *06) and group C2 molecules 
(containing C*01, *03, *07 and *08), respectively [78]. 
Groups C1 and C2 are distinguished by the presence of Ser 
at position 77 and asparagine (Asn) at position 80 of the 1 
helix or Asp at position 77 and a lysine (Lys) at position 80, 
Table 2.  List of Proposed Viral Triggers for Autoimmune Disease 
Virus  Virus Family  Symptoms Caused by Virus  Autoimmune Disease/s 
Adenovirus  Adenoviridae  Upper respiratory infections  GD [91] 
Coxsachie B virus  Picornaviridae 
Gastrointestinal infections and in more extreme cases myocarditis 
(inflammation of the heart) and pericarditis (inflammation of the 
sack surrounding the heart) 
T1D [92-95] 
Hepatitis B  Hepadnaviridae  Liver inflammation  SLE [96, 97] 
Hepatitis C  Hepadnaviridae  Liver inflammation 
MG [98, 99], GD [100, 101], 
T1D [102, 103], SLE [104] 
Herpes simplex virus 1 & 2  Herpesviridae 
Blisters in the skin/lips/mouth/genitals and then infection become 
latent for future re-activation 
MS [105, 106] 
Herpes simplex virus 3  
(Varicella Zoster Virus) 
Herpesviridae 
Causes chicken pox during initial infection and upon reactivation 
can cause shingles 
MS [105, 107] 
Herpes simplex virus 4  
(Epstein Barr Virus) 
Herpesviridae 
Often asymptomatic but can cause infectious mononucleosis result-
ing in fever, sore throat, muscle soreness and fatigue 
RA [108, 109], SLE [108],  
MS [108, 110, 111] 
Herpes simplex virus 5  
(Cytomegalovirus) 
Herpesviridae 
Latent infection that in healthy individuals causes limited  
symptoms but can be more detrimental in immuno-compromised  
individuals 
SLE [112, 113], MS [114] 
Herpes simplex virus 6  Herpesviridae  Infects almost all children causing a rash before becoming latent  MS [105, 115, 116] 
Human Coronavirus (HCoV)  Coronaviridae  Upper respiratory and gastrointestinal tract infection  MS [117] 
Human Foamy Virus  Retroviridae  Asymptomatic 
GD [118, 119], RA [120],  
SLE [120], MG [121] 
Human immunodeficiency  
virus (HIV) 
Retroviridae 
Leads to low levels of CD4+ T cells, resulting in a compromised 
immune system, making the person susceptible to opportunistic 
infection 
SLE [122, 123], MG [123] 
Human T cell leukaemia 
virus (HTLV) 
Retroviridae  T cell leukaemia and T cell lymphoma  GD [124, 125], SLE [126] 
John Cunningham (JC)  
virus 
Polymaviridae 
Asymptomatic unless in immuno-compromised patients where is  
can cause progressive multifocal leukoencephalopathy and other  
diseases 
MS [127-129] 
Parvovirus B19  Paroviridae  Causes childhood exanthema (a widespread rash) 
HT [130], RA [131, 132],  
T1D [132, 133], GD [132],  
MS [134], MG [135] 
Rotavirus  Reoviridae  Infection of the gastrointestinal tract  T1D [136] 
Transfusion transmitted  
(TT) virus 
Circoviridae  Asymptomatic RA  [137] 
GD = Graves’ disease, T1D = type 1 diabetes, RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, MS = multiple sclerosis, MG = Myesthenia Gravis, HT = Hashi-
moto’s thyroiditis. The HLA Region and Autoimmune Disease  Current Genomics, 2007, Vol. 8, No. 7    459 
respectively. KIR/HLA-C interactions can be altered by pep-
tide loading and presentation by HLA-C [79, 80], which 
could suggest that interaction seen in GD and MS of the as-
sociated HLA-C molecules with a given autoantigen/s could 
be affecting KIR binding and that this interaction between 
KIRs and HLA-C could play a role in autoimmune onset [81, 
82]. Variation in the interaction of other molecules that bind 
to HLA class I and monitor HLA class I expression, includ-
ing leukocyte Ig-like receptors (LIRs), members of the Ly49 
family (Ly49) and the CD94/NKG2 family of receptors, 
could also provide another mechanism by which HLA class I 
could lead to AID [76, 77, 83].  
  Non-viral mechanisms have also been proposed includ-
ing: 
i)  protein misfolding causing specific molecules to accu-
mulate in the RER, where they are degraded, poten-
tially causing a pro-inflammatory unfolded protein 
stress response or misfolded proteins themselves to be-
come autoantigenic [48]. 
ii)  Conversion of HLA class I molecules into peptides 
which could then be presented by HLA class II mole-
cules to the immune system and an immune response 
mounted as has been proposed in AS with B*27 [43].  
iii)  Peptide binding and presentation by specific HLA 
molecules as suggested earlier for HLA class II mole-
cules with mechanisms including selection of antigen 
specific CD8+ T cells during thymic education, and 
positive or negative selection of a strong CD8+ T sup-
pressor population [84].  
ARE THERE ANY OTHER HLA ASSOCIATIONS? 
  Once the classical HLA class II and/or class I effects 
have been taken into account it becomes increasingly diffi-
cult to detect further associations, suggesting that even larger 
datasets and new techniques to cover more variation within 
this region are required [55]. It should be noted that although 
HLA class II and class I appear to play a role in almost all 
AIDs, in some, the associations may lie outside of the classi-
cal loci. Strong association of HLA-C with psoriasis was 
detected and presumed to be the etiological variant, until 
further studies suggested that the true etiological variant ac-
tually lies 60kb outside of the HLA-C molecule [85, 86]. 
Although this review has focused on the classical HLA class 
I and II associations which have shown strong and consistent 
association with AID, several other genes within the HLA 
region may be acting as independent risk factors for AID 
(Table  3). Further work is required to determine if these 
genes are true AID etiological variants [87, 88], using tech-
niques, for example, which utilise the development of tag 
SNPs to screen the HLA region [89]. 
CONCLUSIONS 
  With our increased understanding of the complexity 
within the HLA region and the development of new statisti-
cal methodologies to help decipher the unique LD structure 
therein, progress has been made in starting to disentangle the 
associations present [89, 90], providing valuable insights 
into AID mechanisms. Novel therapeutic treatments based 
on these discoveries have already been proposed. The devel-
opment of protease inhibitors designed to alter the antigen 
presenting properties of HLA molecules, by blocking the 
presentation of potentially auto-antigenic peptides, could 
direct the immune system away from a particular antigenic 
motif and in turn the autoimmune disease process [37]. Al-
though clinical use may be some way off, continued research 
on the whole HLA region is vital to increase our understand-
ing of the key mechanisms behind AID and ultimately the 
provision of new therapeutic targets. 
Table 3.  Genes within the HLA Region which have been Proposed to Contribute to Autoimmune Disease (AID) Susceptibility In-
dependently of Known HLA Class I and Class II Association 
Gene Region  Function 
AIDs Proposed to be  
Linked to these Genes 
BAT family  
members 
Class III  Believed to play a role in negatively regulating inflammation.  RA [138-140] 
BTNL2  Class II 
BTNL2 has structure features including an IgC domain which it shares with CD80/CD86, 
which act as co-stimulatory receptors for T cell activation, including interacting with 
CTLA-4, and other molecules involved in T cell inhibition including B7-RP. 
GD [141] 
Complement  
component C4 
Class III 
Plays a role in both the classical and lectin pathways of complement activation which leads 
to several outcomes including activating inflammation, secretion of immunoregulatory 
molecules that fine tune the immune response, clearance of immune complexes, opsoniza-
tion (aiding antibodies to enhance the ability of phagocytic cells to attack bacteria) and 
lysis of bacteria, viruses and cells. 
SLE [142-149] 
MICA/MICB  Class I 
Stress induced molecule found on the surface of epithelial cell lines which is similar to the 
classical class I molecules but does not associate with 2M or bind antigen. 
T1D [150-154],  
MS [155], RA [156, 157] 
TNF  Class III 
A multifunctional cytokine secreted by macrophages and T lymphocytes with wide-ranging 
biological effects including protection from infection, surveillance against tumors and 
stimulation of inflammatory responses. 
RA [158],  
GD [159], SLE [160] 
RA = rheumatoid arthritis, GD = Graves’ disease, SLE = systemic lupus erythematosus, T1D = type 1 diabetes, MS = multiple sclerosis. 460    Current Genomics, 2007, Vol. 8, No. 7  Gough and Simmonds 
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